Biogen Gross Profit increased by 1.8% to $1.82B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $1.80B to $1.82B. Over 4 years (FY 2021 to FY 2025), Gross Profit shows a downward trend with a -4.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved manufacturing efficiency, favorable product mix, or higher pricing power, while a decrease may indicate rising raw material costs, supply chain inefficiencies, or competitive pricing pressure.
Gross profit represents the residual earnings a company retains after deducting the direct costs associated with produci...
Peers in the medical device and diagnostics sector typically maintain high gross margins due to intellectual property and specialized manufacturing, though these vary based on the specific product mix of nutritionals versus high-tech devices.
gross_profit| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.32B | $2.27B | $2.07B | $1.78B | $2.11B | $2.04B | $1.97B | $1.80B | $1.86B | $1.87B | $1.77B | $1.75B | $1.92B | $1.83B | $1.87B | $1.80B | $2.04B | $1.86B | $1.78B | $1.82B |
| QoQ Change | — | -2.1% | -8.5% | -14.3% | +18.4% | -3.1% | -3.2% | -8.8% | +3.5% | +0.4% | -5.5% | -1.1% | +9.8% | -4.8% | +2.4% | -3.7% | +13.3% | -8.8% | -4.1% | +1.8% |
| YoY Change | — | — | — | — | -9.1% | -10.1% | -4.9% | +1.3% | -11.5% | -8.3% | -10.4% | -2.9% | +3.0% | -2.3% | +5.8% | +3.1% | +6.3% | +1.8% | -4.7% | +0.8% |